Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, Gothenburg, Sweden.
Early Product Development, Pharmaceutical Sciences, R&D, AstraZeneca, Gothenburg, Sweden.
Int J Pharm. 2020 May 15;581:119252. doi: 10.1016/j.ijpharm.2020.119252. Epub 2020 Mar 30.
The aim of the present study was to evaluate and interpret the pharmacokinetic profiles after subcutaneous (s.c.) administration of crystalline AZ'72 nano- and microsuspensions to rodents. Both formulations were injected at 1.5 and 150 mg/kg to rats. For the lower dose, the profiles were similar after s.c. injection but extended as compared to oral administration. The overall exposure was higher for nanoparticles compared with microparticles during the investigated period. For the higher dose, injection of both suspensions resulted in maintained plateaus caused by the drug depots but, unexpectedly, at similar exposure levels. After addition of a further stabilizer, pluronic F127, nanosuspensions showed improved exposure with dose and higher exposure compared to larger particles in mice. Obviously, a stabilizer mixture that suits one delivery route is not necessarily optimal for another one. The differences in peak concentration (C) between nano- and microparticles were mainly ascribed to differences in dissolution rate. Plasma profiles in mice showed curves with secondary absorption peaks after intravenous and oral administration, suggesting hepatic recirculation following both administration routes. This process, together with the depot formulation, complicates the analysis of absorption from s.c. administration, i.e. multiple processes were driving the plasma profile of AZ'72.
本研究旨在评估和解释 AZ'72 晶型纳米和微悬浮剂经皮下(s.c.)给药后在啮齿动物体内的药代动力学特征。两种制剂以 1.5 和 150mg/kg 的剂量给大鼠注射。对于较低剂量,s.c. 注射后的药代动力学特征相似,但与口服给药相比,其持续时间更长。在研究期间,纳米颗粒的总体暴露量高于微颗粒。对于较高剂量,两种混悬剂的注射均导致药物储库维持平台期,但出乎意料的是,其暴露水平相似。加入另一种稳定剂 Pluronic F127 后,纳米混悬剂在小鼠中的暴露量随剂量增加,且与较大颗粒相比,暴露量更高。显然,一种适合于一种给药途径的稳定剂混合物对于另一种给药途径不一定是最佳的。纳米颗粒和微颗粒之间的峰浓度(C)差异主要归因于溶解速率的差异。小鼠的血浆曲线在静脉注射和口服给药后出现二次吸收峰,提示两种给药途径均存在肝再循环。这一过程与储库制剂一起使皮下给药的吸收分析复杂化,即多个过程驱动 AZ'72 的血浆特征。